Abstract
It was only in December 2008 that the European Union regulated the approval procedure for tissue engineered products (TEPs). Due to this regulation, TEP is classified as an advanced therapy medicinal product and as such may be recognized as a tool in pharmaceutical biotechnology. This paper gives a short review of the concept, the experimental evaluation and the clinical potency of tissue engineering (TE), with a particular focus on bone tissue engineered products. After a period of great enthusiasm about TE at the end of the 20th century a slight disappointment followed in the early 2000s. The review refers also to the continuously growing scientific interest, accompanied by the still modest representation of TEPs on the medical market. Some remarks are given on a bench-to-clinic road, including criticism concerning data originating from animal experiments. An attempt is made to foresee the still promising future of bone tissue engineered products (BTEPs) in practical use.
Keywords: Bone, Tissue engineering, Medicinal product, Stem cells, Scaffold, intrinsic bioactivity, cytokines, allogenic transplantation, human periosteal cells, autologous marrow stromal cells, sheep metatarsals, pre-cultured cells, cell-based therapy, bone morphogenic proteins (BMP), calcium phosphate ceramics, human embryonic stem cells (hESCs)
Current Pharmaceutical Biotechnology
Title: Bone Tissue Engineering – A Field For New Medicinal Products?
Volume: 12 Issue: 11
Author(s): Malgorzata Lewandowska-Szumiel and Joanna Wojtowicz
Affiliation:
Keywords: Bone, Tissue engineering, Medicinal product, Stem cells, Scaffold, intrinsic bioactivity, cytokines, allogenic transplantation, human periosteal cells, autologous marrow stromal cells, sheep metatarsals, pre-cultured cells, cell-based therapy, bone morphogenic proteins (BMP), calcium phosphate ceramics, human embryonic stem cells (hESCs)
Abstract: It was only in December 2008 that the European Union regulated the approval procedure for tissue engineered products (TEPs). Due to this regulation, TEP is classified as an advanced therapy medicinal product and as such may be recognized as a tool in pharmaceutical biotechnology. This paper gives a short review of the concept, the experimental evaluation and the clinical potency of tissue engineering (TE), with a particular focus on bone tissue engineered products. After a period of great enthusiasm about TE at the end of the 20th century a slight disappointment followed in the early 2000s. The review refers also to the continuously growing scientific interest, accompanied by the still modest representation of TEPs on the medical market. Some remarks are given on a bench-to-clinic road, including criticism concerning data originating from animal experiments. An attempt is made to foresee the still promising future of bone tissue engineered products (BTEPs) in practical use.
Export Options
About this article
Cite this article as:
Lewandowska-Szumiel Malgorzata and Wojtowicz Joanna, Bone Tissue Engineering – A Field For New Medicinal Products?, Current Pharmaceutical Biotechnology 2011; 12 (11) . https://dx.doi.org/10.2174/138920111798376941
DOI https://dx.doi.org/10.2174/138920111798376941 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidative Stress and Mitochondrial Impairment After Treatment with Anti-HIV Drugs: Clinical Implications
Current Pharmaceutical Design Thalidomide: An Overview of its Pharmacological Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design CA125: An Increasingly Promising Biomarker of Heart Failure
Current Pharmaceutical Design Mechanisms of Thrombosis, Available Treatments and Management Challenges Presented by Thromboangiitis Obliterans
Current Medicinal Chemistry Benzodiazepines, Amphetamines, Testosterone, and Sildenafil as New Candidate Drugs for Sexual Interest, Desire and/or Arousal Disorder
Current Psychopharmacology Porphyrin Photosensitised Processes in the Prevention and Treatment of Water- and Vector-Borne Diseases
Current Medicinal Chemistry Efficacy of the Newest COX-2 Selective Inhibitors in Rheumatic Disease
Current Pharmaceutical Design Side Effects of Clozapine and Some Other Psychoactive Drugs
Current Drug Safety Advances in Tissue and Organ Replacement
Current Stem Cell Research & Therapy Molecular Links Between Endothelial Dysfunction and Neurodegeneration in Alzheimer's Disease
Current Alzheimer Research Biocompatibility Studies of Functionalized CoFe2O4 Magnetic Nanoparticles
Current Nanoscience Safety and Complications Reporting Update on the Re-Implantation of Culture-Expanded Mesenchymal Stem Cells Using Autologous Platelet Lysate Technique
Current Stem Cell Research & Therapy Fish Genomes, Comparative Genomics and Vertebrate Evolution
Current Genomics Clinical Use of Aspirin in Ischemic Heart Disease: Past, Present and Future
Current Pharmaceutical Design Role of LXR and ABCA1 in the Pathogenesis of Alzheimers Disease -Implications for a New Therapeutic Approach
Current Alzheimer Research Herbal Compounds with Special Reference to Gastrodin as Potential Therapeutic Agents for Microglia Mediated Neuroinflammation
Current Medicinal Chemistry Small Non-Coding RNAs as Novel Therapeutics
Current Molecular Medicine Role of Genetic Factors in Statins Side-Effects
Cardiovascular & Hematological Disorders-Drug Targets Protective Effects of Curcumin against Lipopolysaccharide-Induced Toxicity
Current Medicinal Chemistry